Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Small Cell Lung Cancer Clinical Trials

A listing of Small Cell Lung Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (1136) clinical trials

The purpose of this research study is to compare any good and bad effects of using the study drug, crizotinib (also known as XALKORI®), after completion of surgery and, in some cases, after chemotherapy and/or radiation therapy for ALK-positive non-small cell lung cancer. The addition of crizotinib may help prevent ...

Phase

The purpose of this research study is to examine lung cancer patients’ surgically removed tumors for certain genetic changes, and to possibly refer these patients to a treatment study with drugs that may specifically target tumors that have these genetic changes. A genetic test will be done to learn if ...

Phase

The purpose of this study is to compare any good and bad effects patients may have when treated with the standard treatment against patients who are treated with the standard treatment plus erlotinib (an investigational drug). You are being asked to take part in this research study because you have ...

Phase

MGCD516 is a receptor tyrosine kinase (RTK) inhibitor shown in preclinical models to inhibit a closely related spectrum of RTKs including MET, AXL, MER, and members of the VEGFR, PDGFR, DDR2, TRK and Eph families. In this study, MGCD516 is orally administered to patients with advanced solid tumor malignancies to ...

Phase

The relatively restricted C4.4a expression pattern provides a target for the selective delivery of a cytotoxic drug to C4.4.a-expressing tumor cells by means of a suitable antibody-drug conjugate. The subject population eligible for the current study will be those subjects with advanced malignancies known to express C4.4a, which are refractory ...

Phase

- This is the first study where BAY1163877 is given to humans. Impact of the study is to evaluate if patients with advanced solid cancers show advanced clinical benefit under the treatment with the pan FGFR inhibitor. Patients (all comers) will receive the study drug treatment in a dose-escalation scheme ...

Phase

For more information please visit: http://clinicaltrials.gov/ct2/show/record/NCT00632853?term=30610&rank=1

Phase

Study to evaluate the long-term safety and efficacy of Darbepoetin Alfa in anemic subjects with Advanced Stage Non-small Cell Lung Cancer receiving multi-cycle chemotherapy. Patient Inclusion Criteria: Subjects with metastatic (stage IV) Non-small Cell Lung cancer, receiving or about receive first line cyclic chemotherapy, life expectancy >6 months, 18 years ...

Phase

Patients with non-small cell lung cancer who have failed two or more prior treatment regimens, to determine overall survival Patient Inclusion Criteria: 18+ years of age, confirmed stage IIIB or non-small cell lung cancer, failed at least 2 prior systemic anti-cancer regimens, disease progression, Patient Exclusion Criteria: Presence of brain ...

Phase

First-line treatment for patients with non-squamous non-small cell lung cancer Patient Inclusion Criteria: Confirmed diagnosis, at least one measurable target lesion, 18+ years of age, life expectancy of >12 weeks Patient Exclusion Criteria: Small cell or carcinoid lung cancer patients are ineligible, untreated brain metastases, history of active malignancy in ...

Phase